Skip to search formSkip to main contentSkip to account menu

MEDI507

Known as: MEDI-507 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Siplizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease
Background. Acute graft-versus-host disease (GVHD) is a major complication of both bone marrow and hematologic stem cell… 
2006
2006
Mechanistic Evaluation of Siplizumab (MEDI-507) Activity on Normal and Malignant T-Lymphocytes.
Siplizumab is a humanized monoclonal antibody that selectively binds human CD2 (huCD2), which is expressed on virtually all cells… 
2004
2004
The anti‐CD2 monoclonal antibody BTI‐322 generates unresponsiveness by activation‐associated T cell depletion
The antihuman CD2 MoAb BTI‐322 (Lo‐CD2a) effectively inhibits T cell responses in vitro to allogeneic cells, which is followed by… 
Highly Cited
2003
Highly Cited
2003
Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.
We initiated a clinical trial of nonmyeloablative haploidentical stem-cell transplantation (SCT) using MEDI-507, an… 
2003
2003
Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2
L'invention concerne l'utilisation d'un antagoniste de CD2, de preference MEDI-507, d'un analogue, d'un derive ou d'un fragment a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)